How does the effectiveness of Emgality and Aimovig compare?

In separate clinical trials that studied how well Emgality (galcanezumab) and Aimovig (erenumab) worked to prevent chronic migraines showed:

• Aimovig had a bigger decrease (-2.5 days) in migraine days per month compared to Emgality (-2.1 days).
• Aimovig had a bigger percentage (16.4%) of patients who had their migraines reduced by half compared to Emgality (13%).

Emgality is also indicated to treat episodic cluster headaches in adults. Aimovig does not have an FDA approved indication to treat episodic cluster headaches.

How do the side effects of Emgality and Aimovig compare?

• Aimovig has a rate of 6% for injection site reactions which is lower than Emgality injection site reactions of 18%.
• Both Aimovig and Emgality have constipation and itchy skin as side effects which affects between 1 and 10% patients.
• Aimovig has other common side effects including tiredness, cramps and muscle spasms.
• Emgality has other common side effects including anti-drug-antibodies (up to 12.5%), dizziness and welts.

Allergy to Latex?

If you are allergic to latex it is important to know that Aimovig prefilled autoinjector device and the Aimovig prefilled syringe device contain dry natural rubber which is derived from latex. You should tell your health professional if you are allergic to latex.

For the Aimovig prefilled autoinjector the part of the device that contains latex is the needle shield within the white or orange cap. For the Aimovig prefilled syringe it is the gray needle cap that contains dry natural rubber.

Table for Aimovig and Emgality

These figures are from individual drug clinical trials and not from comparison trials.